New antibody weapon tested in battle against tough head & neck cancers
Disease control
Completed
This completed Phase 3 trial tested whether adding an experimental antibody drug (C225) to standard chemotherapy (cisplatin) worked better for people with advanced head and neck cancer that had spread or returned. About 114 patients were randomly assigned to get either the real a…
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC